---
title: Improve Parkinson detection and tracking
nct_id: NCT05370079
phase: NA
status: RECRUITING
sponsor: Hospices Civils de Lyon
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05370079"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05370079"
last_fetched: "2026-05-10T14:02:56.216Z"
source: "Parkinson's Pathways (curated)"
---
# Improve Parkinson detection and tracking

**Goal (in five words):** Improve Parkinson detection and tracking

**Official Title:** Control Cohort CTRL COH

**Trial ID:** [NCT05370079](https://clinicaltrials.gov/study/NCT05370079)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Hospices Civils de Lyon
- **Target Enrollment:** 350 participants
- **Start Date:** 2023-08-08
- **Completion Date:** 2028-08-08
- **Conditions:** Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis
- **Interventions:** Collection of biological sample (blood and/or CSF)
- **Intervention Types:** BIOLOGICAL

## Summary For Families

The goal is to build a control cohort of blood and spinal fluid samples so researchers can identify and compare biomarkers tied to Parkinson's and other conditions, helping future studies detect, track, or tell diseases apart. Participants give blood and sometimes cerebrospinal fluid, which scientists analyze for proteins, immune markers, and other signals, and the visit does not test a drug or change your medications like levodopa. Adults 18 and older with Parkinson's, ALS, glioblastoma, certain non‑neurological cancers, or rheumatoid arthritis who can give consent may join, while people with paraneoplastic neurological syndromes or autoimmune encephalitis and those under guardianship are excluded; about 350 participants are planned.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* patient with consent
* patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.

Exclusion Criteria:

* refusal consent
* patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
* patient under guardianship
```

## Locations (1)

- Hospices Civils de Lyon, Bron, France _(45.7386, 4.9130)_
  - Jerome HONNORAT, Pr — (CONTACT) — (33) 4 72 35 78 06 — jerome.honnorat@chu-lyon.fr
  - Jerome HONNORAT — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Jerome Honnorat, Pr — (CONTACT) — (33) 4 72 35 78 06 — jerome.honnorat@chu-lyon.fr
- Géraldine Picard, CRA — (CONTACT) — (33) 4 72 35 58 42 — geraldine.picard@chu-lyon.fr

---

*Canonical: https://parkinsonspathways.com/trial/NCT05370079*  
*HTML version: https://parkinsonspathways.com/trial/NCT05370079*  
*Source data: https://clinicaltrials.gov/study/NCT05370079*